MACROGENICS, INC. Increase (Decrease) in Prepaid Expense
MACROGENICS, INC. (MGNX) reported Increase (Decrease) in Prepaid Expense of -$2.77 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidExpense · last filed 2026-03-09
- MACROGENICS, INC. increase (decrease) in prepaid expense for the quarter ending 2020-12-31 was $6.35M.
- MACROGENICS, INC. increase (decrease) in prepaid expense for the quarter ending 2020-09-30 was $2.44M, a 1.50% increase year-over-year.
- MACROGENICS, INC. increase (decrease) in prepaid expense for the quarter ending 2020-06-30 was -$4.44M, a 439.56% decline year-over-year.
- MACROGENICS, INC. increase (decrease) in prepaid expense for the quarter ending 2020-03-31 was $1.34M, a 29.28% decline year-over-year.
- MACROGENICS, INC. increase (decrease) in prepaid expense for fiscal 2025 was -$2.77M, a 276.71% decline from fiscal 2024.
- MACROGENICS, INC. increase (decrease) in prepaid expense for fiscal 2024 was $1.57M.
- MACROGENICS, INC. increase (decrease) in prepaid expense for fiscal 2023 was -$215.00K.
- MACROGENICS, INC. increase (decrease) in prepaid expense for fiscal 2022 was -$11.01M, a 362.87% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense 3 month | Increase (Decrease) in Prepaid Expense 3 month as first filed | Increase (Decrease) in Prepaid Expense 6 month | Increase (Decrease) in Prepaid Expense 9 month | Increase (Decrease) in Prepaid Expense 9 month as first filed | Increase (Decrease) in Prepaid Expense 12 month | Increase (Decrease) in Prepaid Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | -$2.77M 10-K · filed 2026-03-09 | ||||||
| 2024-12-31 | $1.57M 10-K · filed 2026-03-09 | ||||||
| 2023-12-31 | -$215.00K 10-K · filed 2026-03-09 | ||||||
| 2022-12-31 | -$11.01M 10-K · filed 2025-03-20 | ||||||
| 2021-12-31 | $4.19M 10-K · filed 2024-03-07 | ||||||
| 2020-12-31 | $6.35M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-15 | $8.79M derived: sum of 2 quarters · filed 2023-03-15 | $4.35M derived: sum of 3 quarters · filed 2023-03-15 | $5.70M 10-K · filed 2023-03-15 | |||
| 2020-09-30 | $2.44M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$2.00M derived: sum of 2 quarters · filed 2020-11-04 | -$654.00K 10-Q · filed 2020-11-04 | -$1.39M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-06-30 | -$4.44M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | -$3.09M 10-Q · filed 2020-07-31 | -$3.83M derived: sum of 3 quarters · filed 2022-02-24 | -$1.42M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2020-03-31 | $1.34M 10-Q · filed 2020-05-05 | $611.00K derived: sum of 2 quarters · filed 2022-02-24 | $3.01M derived: sum of 3 quarters · filed 2022-02-24 | $4.32M derived: sum of 4 quarters · filed 2022-02-24 | |||
| 2019-12-31 | -$734.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.67M derived: sum of 2 quarters · filed 2022-02-24 | $2.98M derived: sum of 3 quarters · filed 2022-02-24 | $4.88M 10-K · filed 2022-02-24 | |||
| 2019-09-30 | $2.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $3.71M derived: sum of 2 quarters · filed 2020-11-04 | $5.61M 10-Q · filed 2020-11-04 | $7.70M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-31 | $3.21M 10-Q · filed 2020-07-31 | $5.30M derived: sum of 3 quarters · filed 2021-02-25 | $6.44M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | $1.90M 10-Q · filed 2020-05-05 | $3.99M derived: sum of 2 quarters · filed 2021-02-25 | $5.13M derived: sum of 3 quarters · filed 2021-02-25 | $4.98M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | $3.23M derived: sum of 2 quarters · filed 2021-02-25 | $3.08M derived: sum of 3 quarters · filed 2021-02-25 | $3.25M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | $1.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $987.00K derived: sum of 2 quarters · filed 2019-11-06 | $1.16M 10-Q · filed 2019-11-06 | $1.05M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-06-30 | -$155.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $22.00K 10-Q · filed 2019-07-31 | -$88.00K derived: sum of 3 quarters · filed 2020-02-25 | -$835.00K derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2018-03-31 | $177.00K 10-Q · filed 2019-05-01 | $67.00K derived: sum of 2 quarters · filed 2020-02-25 | -$680.00K derived: sum of 3 quarters · filed 2020-02-25 | -$1.69M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2017-12-31 | -$110.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | -$857.00K derived: sum of 2 quarters · filed 2020-02-25 | -$1.87M derived: sum of 3 quarters · filed 2020-02-25 | -$332.00K 10-K · filed 2020-02-25 | |||
| 2017-09-30 | -$747.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$1.76M derived: sum of 2 quarters · filed 2018-11-07 | -$222.00K 10-Q · filed 2018-11-07 | $1.95M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-06-30 | -$1.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $525.00K 10-Q · filed 2018-08-07 | $2.70M derived: sum of 3 quarters · filed 2019-02-26 | $226.00K derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2017-03-31 | $1.53M 10-Q · filed 2018-05-07 | $3.71M derived: sum of 2 quarters · filed 2019-02-26 | $1.24M derived: sum of 3 quarters · filed 2019-02-26 | $3.31M derived: sum of 4 quarters · filed 2019-02-26 | |||
| 2016-12-31 | $2.17M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$299.00K derived: sum of 2 quarters · filed 2019-02-26 | $1.78M derived: sum of 3 quarters · filed 2019-02-26 | $1.68M 10-K · filed 2019-02-26 | |||
| 2016-09-30 | -$2.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$392.00K derived: sum of 2 quarters · filed 2017-11-08 | -$495.00K 10-Q · filed 2017-11-08 | -$673.00K derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | $2.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $1.98M 10-Q · filed 2017-08-02 | $1.80M derived: sum of 3 quarters · filed 2018-02-27 | $716.00K derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | -$103.00K 10-Q · filed 2017-05-03 | -$281.00K derived: sum of 2 quarters · filed 2018-02-27 | -$1.36M derived: sum of 3 quarters · filed 2018-02-27 | -$1.91M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | -$178.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$1.26M derived: sum of 2 quarters · filed 2018-02-27 | -$1.81M derived: sum of 3 quarters · filed 2018-02-27 | -$2.40M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | -$1.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$1.63M derived: sum of 2 quarters · filed 2016-11-02 | -$2.23M 10-Q · filed 2016-11-02 | -$469.00K derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | -$551.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$1.15M 10-Q · filed 2016-08-03 | $613.00K derived: sum of 3 quarters · filed 2017-02-28 | $966.00K derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | -$594.00K 10-Q · filed 2016-05-04 | $1.16M derived: sum of 2 quarters · filed 2017-02-28 | $1.52M derived: sum of 3 quarters · filed 2017-02-28 | $1.68M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | $1.76M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $2.11M derived: sum of 2 quarters · filed 2017-02-28 | $2.27M derived: sum of 3 quarters · filed 2017-02-28 | $3.24M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | $353.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | $516.00K derived: sum of 2 quarters · filed 2015-11-04 | $1.48M 10-Q · filed 2015-11-04 | $1.35M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | $163.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | $1.13M 10-Q · filed 2015-08-05 | $996.00K derived: sum of 3 quarters · filed 2016-02-29 | $2.03M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | $965.00K 10-Q · filed 2015-05-06 | $964.80K 10-Q · filed 2014-05-06 | $833.00K derived: sum of 2 quarters · filed 2016-02-29 | $1.87M derived: sum of 3 quarters · filed 2016-02-29 | $1.88M derived: sum of 4 quarters · filed 2016-02-29 | ||
| 2013-12-31 | -$132.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $901.00K derived: sum of 2 quarters · filed 2016-02-29 | $914.30K derived: sum of 3 quarters · filed 2016-02-29 | $834.00K 10-K · filed 2016-02-29 | $834.07K 10-K · filed 2014-03-20 | ||
| 2013-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | $1.05M derived: sum of 2 quarters · filed 2014-11-12 | $966.00K 10-Q · filed 2014-11-12 | $965.82K 10-Q · filed 2013-11-12 | $987.77K derived: sum of 4 quarters · filed 2015-03-03 | ||
| 2013-06-30 | $13.30K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | -$67.00K 10-Q · filed 2014-08-05 | -$45.23K derived: sum of 3 quarters · filed 2015-03-03 | ||||
| 2013-03-31 | -$80.30K 10-Q · filed 2014-05-06 | -$58.53K derived: sum of 2 quarters · filed 2015-03-03 | |||||
| 2012-12-31 | $21.77K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-03 | $91.00K 10-K · filed 2015-03-03 | $91.16K 10-K · filed 2014-03-20 | ||||
| 2012-09-30 | $69.23K 10-Q · filed 2013-11-12 | ||||||
| 2011-12-31 | -$76.88K 10-K · filed 2014-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |